Tulisokibart Hidradenitis Suppurativa Trial Meets Endpoint
Tulisokibart hidradenitis suppurativa results: Merck’s Phase 2b trial met its HiSCR50 primary endpoint at week 16, with 72% response on the high dose.
Tag: Tulisokibart
Read More